Articles from multiQure SA

multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
WARSAW, POLAND / ACCESS Newswire / November 19, 2026 / multiQure S.A. (WSE:MQR), a biotechnology company developing an RNAi gene therapy for Huntington's disease, is moving into the manufacturing phase of its MQ-201 therapy. The Company has selected Andelyn Biosciences Inc. of Columbus, Ohio, as its manufacturing partner. Andelyn is a specialist gene therapy vector manufacturer whose facility has passed an FDA pre-license inspection. Andelyn will be responsible for the GMP manufacture of the plasmids and the AAV5 vector - the material intended to be administered to the first patients. Work starts immediately: the Company has signed an agreement for the first stage, and a framework agreement is being finalized.
By multiQure SA · Via ACCESS Newswire · November 19, 2026
multiQure Sees Strong Interest in Partnering Talks Ahead of BIO-Europe 2026
14 one-on-one meetings already scheduled two weeks before the event
By multiQure SA · Via ACCESS Newswire · October 27, 2026